Girentuximab 

N/A

Report date: 2024/06/26 09:24:32

Base Information

Drug NameGirentuximab 
Drug Alias Name吉仑妥昔单抗GirentuximabumMonoclonal antibody G250吉瑞昔单抗Rencarex +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionImmunostimulantsAnti-Carbonic anhydrase IX
TargetsCarbonic anhydrase IX
Therapy Area/IndicationsKidney NeoplasmsCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[6] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesWilex AG
China Registration ClassN/A

Develop Information

Active CompaniesWilex AGTelix Pharmaceuticals Ltd
Inactive CompaniesRadboud University Medical CenterHeidelberg Pharma AG
Active IndicationsCarcinoma, Renal Cell
Inactive IndicationsKidney Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG